Product Description
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Chile | China | Egypt | Ireland | Pakistan | Peru | Russia | Taiwan | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Shijiazhuang People's Hospital
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ChiCTR2400089926 | N/A |
Recruiting |
Stroke |
2025-08-31 |
|
| EH | N/A |
Unknown status |
Brain Diseases|Hepatic Encephalopathy|Intellectual Disability |
2020-01-01 |